These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686 [TBL] [Abstract][Full Text] [Related]
29. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients]. Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677 [No Abstract] [Full Text] [Related]
30. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700 [TBL] [Abstract][Full Text] [Related]
32. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379 [TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy for Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810 [No Abstract] [Full Text] [Related]
34. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028 [TBL] [Abstract][Full Text] [Related]
35. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
36. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048 [TBL] [Abstract][Full Text] [Related]
37. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401 [TBL] [Abstract][Full Text] [Related]
39. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631 [TBL] [Abstract][Full Text] [Related]
40. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]